Quince Therapeutics (QNCX) Retained Earnings (2018 - 2026)

Quince Therapeutics has reported Retained Earnings for 9 years, with the latest figure at -$500.0 million in Q2 2026.

• On a quarterly basis, Retained Earnings fell 221.05% year-over-year to -$500.0 million in Q2 2026; TTM through Jun 2026 was -$500.0 million, a 221.05% decrease from a year earlier, with the FY2025 full-year figure at -$460.5 million, down 213.24% from the prior year.
• Retained Earnings was -$500.0 million for Q2 2026 at Quince Therapeutics, down from $435.6 million in the prior quarter.
• The five-year high for Retained Earnings was $435.6 million in Q1 2026, with the low at -$500.0 million in Q2 2026.
• Average Retained Earnings over 5 years is -$172.9 million, with a median of -$303.0 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Retained Earnings surged 227.21% in 2024, then sank 221.05% in 2026.
• Over 5 years, Retained Earnings stood at -$288.3 million in 2022, then retreated by 10.89% to -$319.6 million in 2023, then soared by 227.21% to $406.6 million in 2024, then slumped by 213.24% to -$460.5 million in 2025, then retreated by 8.6% to -$500.0 million in 2026.
• The last three Retained Earnings figures came in at -$500.0 million (Q2 2026), $435.6 million (Q1 2026), and -$460.5 million (Q4 2025), per Business Quant data.